)
)
Regulus Therapeutics Inc Investor Relations Material
Latest events
Study Update
Regulus Therapeutics Inc
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Regulus Therapeutics Inc
Access all reports
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative drugs that target microRNAs. These microRNAs play a crucial role in regulating gene expression, and by modulating them, Regulus aims to treat a variety of diseases. The company's primary focus is on developing treatments for genetically based kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD), with its lead candidate RGLS8429 currently in clinical trials. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Key slides for Regulus Therapeutics Inc
Study Update
Regulus Therapeutics Inc
Study Update
Regulus Therapeutics Inc
Latest articles
)
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
RGLS
Country
🇺🇸 United States